| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
OdDHL targets the LasR transcriptional activator in P. aeruginosa, where it binds and activates the expression of key virulence factors. In mammalian cells, OdDHL interacts with multiple targets, including the peroxisome proliferator-activated receptor gamma (PPARγ), where it can compete with PPARγ agonists. OdDHL also modulates NF-κB, ERK, and caspase signaling pathways. Additionally, lipid rafts mediate the attachment of OdDHL to porcine intestinal cells, initiating apoptosis through mitochondrial and death receptor pathways.
|
|---|---|
| ln Vitro |
OdDHL demonstrates concentration-dependent inhibition of U46619-induced contractions of porcine coronary artery (1–30 μM) through a largely endothelium-independent mechanism. It suppresses cytokine production in macrophages and inhibits T-cell differentiation and cytokine production. OdDHL induces apoptosis in various cell types and modulates immune responses. In breast tumor microenvironment studies, OdDHL treatment decreased cell viability in a cell-type and microenvironment-dependent manner.
|
| ln Vivo |
In vivo administration of OdDHL modulates the course of antibody responses, increasing ovalbumin-specific IgG1 but not IgG2a in OdDHL-treated OVA-immunized BALB/c mice. In a piglet animal model, OdDHL directly damages intestinal cells in weaned piglets, disrupting the intestinal barrier. OdDHL induces apoptosis in porcine intestinal cells through mitochondrial and death receptor pathways, compromising intestinal barrier integrity. In mouse models, OdDHL induces apoptosis of intestinal cells and intestinal barrier damage.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for OdDHL involve measuring its interaction with PPARγ using competitive binding assays. The compound's ability to activate LasR can be assessed using reporter gene assays in P. aeruginosa. For mammalian cell studies, OdDHL's effects on NF-κB and MAPK signaling can be evaluated using Western blotting or ELISA for phosphorylated proteins. Binding to lipid rafts can be assessed using membrane fractionation and cholesterol depletion experiments.
|
| Cell Assay |
In vitro cellular assays for OdDHL involve treating 16HBE human bronchial epithelial cells or other mammalian cell lines with varying concentrations of the compound (typically 1-30 μM). Cytokine production (e.g., IL-8) is measured using ELISA. T-cell differentiation and cytokine production are assessed using a defined in vitro model of antigen responses by TCR-transgenic mouse splenic CD4 T cells. Apoptosis is evaluated by TUNEL assays, Annexin V staining, or caspase activity assays.
|
| Animal Protocol |
In vivo animal experiments for OdDHL involve administering the compound to BALB/c mice (for antibody response studies) or piglets (for intestinal barrier studies). In piglet models, OdDHL is administered to weaned piglets, and intestinal barrier integrity is assessed by histological analysis and TUNEL assays. In mouse models, OdDHL-induced apoptosis of intestinal cells is evaluated. Antibody responses are measured by ELISA for antigen-specific immunoglobulins.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for OdDHL are limited. As a small signaling molecule (molecular weight ~297.4), OdDHL is diffusible and can partition into lipid bilayers due to its amphipathic nature. The compound is produced by P. aeruginosa and is involved in intercellular signaling. Its stability in biological systems and its metabolism by host cells are areas of ongoing research. OdDHL is typically used in in vitro and in vivo research settings at concentrations ranging from 1-30 μM.
|
| Toxicity/Toxicokinetics |
OdDHL has been shown to induce intestinal barrier damage in piglets via lipid raft-mediated apoptosis pathway. In mouse models, OdDHL induces apoptosis of intestinal cells and disrupts intestinal barrier integrity. The compound's ability to modulate immune responses and induce apoptosis suggests potential pathogenic effects in chronic infections. Standard laboratory safety precautions should be followed when handling this compound, as it is a bacterial virulence factor.
|
| References |
|
| Additional Infomation |
N-(3-oxododecanoyl)-L-homoserine lactone is an N-acyl-L-homoserine lactone with a 3-oxododecanoyl substituent. It is a bacterial metabolite. It is both N-(3-oxododecanoyl)homoserine lactone and N-acyl-L-homoserine lactone. It is the enantiomer of N-(3-oxododecanoyl)-D-homoserine lactone.
OdDHL (CAS#: 168982-69-2) has the molecular formula C16H27NO4 and a molecular weight of approximately 297.4. It is also known as 3-oxo-C12-HSL. OdDHL is a well-characterized member of the N-acyl homoserine lactone (AHL) family of bacterial signaling molecules. It is the primary signal molecule for the LasR receptor system in P. aeruginosa. The compound regulates the expression of key virulence factors including exotoxin A, elastase, alkaline protease, and haemolysin. It is for research use only. |
| Molecular Formula |
C16H27NO4
|
|---|---|
| Molecular Weight |
297.39
|
| Exact Mass |
297.194
|
| CAS # |
168982-69-2
|
| PubChem CID |
3246941
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
519.4±50.0 °C at 760 mmHg
|
| Flash Point |
267.9±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.484
|
| LogP |
2.02
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
21
|
| Complexity |
354
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O
|
| InChi Key |
PHSRRHGYXQCRPU-AWEZNQCLSA-N
|
| InChi Code |
InChI=1S/C16H27NO4/c1-2-3-4-5-6-7-8-9-13(18)12-15(19)17-14-10-11-21-16(14)20/h14H,2-12H2,1H3,(H,17,19)/t14-/m0/s1
|
| Chemical Name |
3-oxo-N-[(3S)-2-oxooxolan-3-yl]dodecanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (336.26 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3626 mL | 16.8129 mL | 33.6259 mL | |
| 5 mM | 0.6725 mL | 3.3626 mL | 6.7252 mL | |
| 10 mM | 0.3363 mL | 1.6813 mL | 3.3626 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
